New Delhi, Dec 24 (IANS) Aurobindo Pharma Limited and Covaxx, a US-based company, have entered into an Exclusive License Agreement to produce, market and manufacture UB-612 for India and the UN Children’s Fund (Unicef) agency, the first Multitope Peptide-based vaccine to combat Covid-19.
For the vaccine product, COVAXX is currently performing a Phase 1 clinical trial.
Commenting on the extension, N. “We are proud to partner with COVAXX in developing the first-ever synthetic peptide-based vaccine to combat the Covid-19 pandemic. This vaccine has immense potential in eliminating shedding, and hence containing, the spread of the pandemic.”We are proud to partner with COVAXX to create the first ever synthetic peptide-based vaccine to combat the pandemic of Covid-19. This vaccine has immense potential to prevent the spread of the pandemic from shedding and thereby containing.
Under the signed agreement, Aurobindo Pharma acquired exclusive rights in India and Unicef to develop, produce and distribute the Covaxx UB-612 vaccine, as well as non-exclusive rights in other select emerging and developed markets.
The completed doses of UB-612 will be manufactured by Aurobindo at its Hyderabad plant.
Aurobindo has a multi-dose presentation capacity of 220 million (22 crore) doses and is constructing additional facilities with a total capacity of approximately 480 million (48 crore) doses by June 2021.
“Covaxx is committed to providing an equitable distribution of UB-612 by prioritizing emerging markets where the unmet need is greatest,” said Mei Mei Hu, co-founder and CEO of COVAXX.
We need to create partners with the strongest capabilities, such as Aurobindo, during this global health crisis response, to prioritize the production and delivery of our vaccine. As one of the leading industry players with a strong track record of vaccine implementation and investment, Aurobindo Pharma is the ideal partner to advance UB-612 in India and other emerging nations and to help our vaccine execution and investment.